Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy.
Noninvasive in vivo quantitation of boron is necessary for obtaining pharmacokinetic data on candidate boronated delivery agents developed for boron neutron capture therapy (BNCT). Such data, in turn, would facilitate the optimization of the temporal sequence of boronated drug infusion and neutron irradiation. Current approaches to obtaining such pharmacokinetic data include: positron emission tomography employing F-18 labeled boronated delivery agents (e.g., p-boronophenylalanine), ex vivo neutron activation analysis of blood (and very occasionally tissue) samples, and nuclear magnetic resonance (NMR) techniques. In general, NMR approaches have been hindered by very poor signal to noise achieved due to the large quadrupole moments of B-10 and B-11 and (in the case of B-10) very low gyromagnetic ratio, combined with low physiological concentrations of these isotopes under clinical conditions. This preliminary study examines the feasibility of proton NMR spectroscopy for such applications. We have utilized proton NMR spectroscopy to investigate the detectability of p-boronophenylalanine fructose (BPA-f) at typical physiological concentrations encountered in BNCT. BPA-f is one of the two boron delivery agents currently undergoing clinical phase-I/II trials in the U.S., Japan, and Europe. This study includes high-resolution 1H spectroscopic characterization of BPA-f to identify useful spectral features for purposes of detection and quantification. The study examines potential interferences, demonstrates a linear NMR signal response with concentration, and presents BPA NMR spectra in ex vivo blood samples and in vivo brain tissues.
Zuo
C S
CS
Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA. czuo@bidmc.harvard.edu
Prasad
P V
PV
Busse
P
P
Tang
L
L
Zamenhof
R G
RG
D001896:Boron Compounds / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics*; D016754:Boron Neutron Capture Therapy; D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000473:pathology* / Q000532:radiotherapy; D017666:Deuterium Oxide; D005632:Fructose / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D015394:Molecular Structure; D019047:Phantoms, Imaging; D011838:Radiation-Sensitizing Agents / Q000032:analysis / Q000493:pharmacokinetics*; D012995:Solubility; D014018:Tissue Distribution; D014867:Water
C089739:4-boronophenylalanine-fructose; D001896:Boron Compounds; D011838:Radiation-Sensitizing Agents; D014867:Water; D005632:Fructose; D017666:Deuterium Oxide